Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities

v3.10.0.1
Accrued expenses and other current liabilities
 9 Months Ended
Sep. 30, 2018
Accrued expenses and other current liabilities  
Accrued expenses and other current liabilities

 

Note 9 — Accrued expenses and other current liabilities

 

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

September 30,

 

December 31,

 

 

 

2018

 

2017

 

Accrued clinical and development expenditure

 

$
9,566

 

$
10,065

 

Accrued employee expenses

 
6,897

 
6,592

 

VAT

 
3,388

 
5,741

 

Other accrued expenditure

 
3,812

 
4,446

 

Other liabilities

 
651

 
357

 

 

 

 

 

 

 

 

 

$
24,314

 

$
27,201

 

 

 

 

 

 

 

 

 

 

The Company typically has a receivable for VAT.  As of December 31, 2017 and as of September 30, 2018, there was a VAT payable due to VAT arising on the milestone payments invoiced to GSK in 2017 and three months ended September 30,2018.